Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope
about
The Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid SyndromeIndications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura.Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.Recent developments in our understanding of the antiphospholipid syndrome.Antibodies against domain I of β2-glycoprotein I: the one and only?Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Anti-β2-glycoprotein I antibodies.Antiphospholipid antibodies mediate autoimmunity against dying cells.Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases.New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies.The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.Perception of self: distinguishing autoimmunity from autoinflammation.Cellular misfolded proteins rescued from degradation by MHC class II molecules are possible targets for autoimmune diseases.Danger signals: Chemotherapy enhancers?Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.A biomimetic sensor surface to detect anti-β2-glycoprotein-I antibodies as a marker for antiphospholipid syndrome.
P2860
Q28069430-09C99796-6176-455A-822A-94E9C1229A19Q33402759-4C2E5EF1-A77A-462A-9203-C1E6B88D22DAQ34069117-7ECC9A84-CD36-4EBB-9872-005A24CB1705Q34700533-C3A0F5CF-7A11-474D-8F06-9B712E12D01AQ36037794-305CFA47-1065-4546-8047-5E4633DEF7E3Q37991066-DB330A26-E236-480A-A367-0A05F421F635Q38013590-E91052FA-4EF5-43C7-87C0-7234A0D181D8Q38048706-DD2AD98A-43C9-411A-B474-A1694DFBB717Q38108396-9A05A321-23AE-488B-9E08-44C035574FACQ38109906-C9580DBD-3D7D-4E7C-9953-D61814EA9828Q38166204-5C865F97-B1B1-43D6-AB86-9EA77905CBB8Q38175886-86251325-CE2F-46DF-8F13-10583C9B9070Q38374306-53F47B38-DE30-4F82-9653-B07D38E0CB18Q38474054-CA700C0B-3C94-4CD2-A6C1-4AAFD65365B1Q38588610-B9A73141-0492-4786-B98D-B595A85EACD3Q47659090-63023DEA-9362-406B-9CD7-5A1A78492569Q47998109-5D512690-5A45-460B-AF39-2E56E63E430EQ51541899-43B6CA37-D287-4DC1-955D-9BC146D892EC
P2860
Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2011
@uk
name
Immune responses against domai ...... a cryptic immunogenic epitope
@en
Immune responses against domai ...... a cryptic immunogenic epitope
@nl
type
label
Immune responses against domai ...... a cryptic immunogenic epitope
@en
Immune responses against domai ...... a cryptic immunogenic epitope
@nl
prefLabel
Immune responses against domai ...... a cryptic immunogenic epitope
@en
Immune responses against domai ...... a cryptic immunogenic epitope
@nl
P2093
P2860
P356
P1476
Immune responses against domai ...... a cryptic immunogenic epitope
@en
P2093
Bas de Laat
Berdien Siregar
Martijn F Gebbink
Miranda van Berkel
Philip G de Groot
P2860
P304
P356
10.1002/ART.30633
P577
2011-12-01T00:00:00Z